2. UroToday Home
  3. Video Lectures

Advanced Bladder Cancer Videos

SunRISe-4 Examines Neoadjuvant Cetrelimab and Gem-iDRS Prior to Cystectomy in Cisplatin-Ineligible Patients - Sarah Psutka
EV-PRIME: Enfortumab Vedotin and Pembrolizumab with Radiation in Patients Declining Cystectomy - Vadim Koshkin
NIAGARA Trial Explores Urinary Tumor DNA as a Biomarker in Bladder Cancer - Michiel Van Der Heijden
Artificial Intelligence Applied to TURBT Specimens in Muscle-Invasive Bladder Cancer - Yair Lotan
Indi-Blade Study Tests Ipilimumab-Nivolumab Followed by Chemoradiotherapy in Advanced Bladder Cancer - Michiel Van Der Heijden & Jan-Jaap Mellema
Perioperative Immunotherapy Versus Risk-Adapted Adjuvant Therapy in MIBC - Patrizia Giannatempo & Thomas Powles
KEYMAKER Substudy Tests Triplet Combinations with EV-Pembro in First-Line Bladder Cancer - Avivit Peer
Bladder Preservation After Neoadjuvant EV+Pembrolizumab - Bogdana Schmidt & Fernando Maluf
EV-PRIME Assesses Safety and Efficacy of Combined Systemic and Local Therapy in MIBC - Raj Satkunasivam
HCRN GU 20-444: Pembrolizumab After TURBT for Bladder‑Sparing in Cisplatin‑Ineligible MIBC - Jonathan Anker
Phase II Trial of Neoadjuvant Sasanlimab and SBRT as an In Situ Vaccine in Cisplatin-Ineligible MIBC - Raj Satkunasivam
Graphical Reconstruction Method Compares Neoadjuvant Regimens in Cisplatin-Ineligible MIBC - Brigida Maiorano
ctDNA Dynamics in Advanced Urothelial Cancer - Jeannie Hoffman-Censits
Women Leading Change in Bladder Cancer: Addressing Diagnostic Delays and Unique Needs - Jeannie Hoffman-Censits
JAVELIN Bladder Medley: Evaluating Checkpoint Inhibitor Combinations After Chemotherapy - Jeannie Hoffman-Censits
IMvigor011 Explores ctDNA Dynamics in Adjuvant Therapy for Urothelial Cancer - Thomas Powles
Evaluating EV Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: KEYNOTE-B15 Results - Matthew Galsky
Phase III SunRISe-2 Trial Compares Gem-iDRS and Cetrelimab to Chemoradiation for MIBC Bladder Preservation - Andrea Necchi
IZABRIGHT Trial Tests Dual HER1/HER3 ADC Against Platinum Chemotherapy in Urothelial Cancer - Thomas Powles
Investigating Pembrolizumab Alone with Response-Guided Bladder Sparing in MIBC - Matthew Galsky
ctDNA to Guide Response-Adapted Bladder Preservation in MIBC: Investigating a Strategy from the Integrated RETAIN Trials Analysis - Pooja Ghatalia
AUC3 Multidisciplinary Consensus Conference Addresses Nuanced Clinical Scenarios in Urologic Cancers - Rana McKay
Global Phase II Trial Explores HER2-Directed Therapy Across Multiple Expression Levels - Thomas Powles
Tracking Circulating Tumor DNA in Patients Undergoing Chemoradiation for Bladder Cancer - Kent Mouw
Exploring KDM6A as a Clinically Actionable Biomarker in Bladder Cancer - Sangeeta Goswami
Bladder Preservation After Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer - Ashish Kamat
AI Biomarker Analyzes TURBT Pathology to Predict Post-Cystectomy Survival in MIBC - Yair Lotan
Analysis of ctDNA in IMvigor011 Informs Adjuvant Therapy Decisions for Muscle-Invasive Bladder Cancer - Matthew Galsky
Phase 3 KEYNOTE-905 Trial Investigates Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - Christof Vulsteke
KEYNOTE-905 Evaluates Perioperative EV+Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - Hristos Kaimakliotis
SUO 2025 Preview: Bladder Cancer Data from BCG-Unresponsive to Metastatic Disease - Patrick Hensley
Scar-Like Bladder Cancer Tumors After Therapy Linked to Favorable Patient Prognosis - Joep de Jong
HER2 in Bladder Cancer: A Frequent but Complex and Dynamic Biomarker - Daniele Raggi
Patient Selection and Outcomes for Partial Cystectomy in Muscle-Invasive Bladder Cancer - Wei Shen Tan
Analysis of ctDNA After Trimodal Therapy for Muscle-Invasive Bladder Cancer - Dekuang Zhao
Health-Related Quality of Life Outcomes from the NIAGARA Trial in Bladder Cancer - Michiel Van Der Heijden
Final Results of the SunRISe-4 Study in Muscle-Invasive Bladder Cancer - Andrea Necchi
Phase 2 Trial of Neoadjuvant Nivolumab and Visugromab in Bladder Cancer Patients - Andrea Necchi
Analysis of MRI Use in the Diagnostic Pathway for Bladder Cancer - Nicholas James
Evaluating Chemotherapy De-Escalation in First-Line Urothelial Carcinoma: DISCUS Trial - Enrique Grande
Pre-ESMO 2025 Highlights - Rashid Sayyid & Zachary Klaassen
STARBURST-1: A Cohort Study to Develop a Complete Response Signature in Bladder Cancer - Alexandra Masson-Lecomte
Multidisciplinary and Global Perspectives on Bladder Cancer Management - Shilpa Gupta, Patrick Hensley & Roger Li
Addressing Limitations in Current Toxicity Reporting for Bladder Cancer Therapies - Shilpa Gupta
Biomarkers for Guiding Bladder Cancer Treatment Decisions - Andrea Necchi
RNA and DNA Biomarkers in Trimodal Therapy for Bladder Cancer - Kent Mouw
Considerations for Treating Bladder Cancer in an Aging Patient Population - Tullika Garg
Phase III EV-302 Trial Reports Outcomes with 2.5 Years of Follow-Up, Journal Club - Rashid Sayyid & Zachary Klaassen
Phase II Trial of Neoadjuvant PD-1 and Gemcitabine/Cisplatin for Bladder Preservation - Alexander Wei
Cost-Effectiveness Comparison of Bladder Preservation vs Radical Surgery - Daniel Joyce
Vitamin C Plus Chemotherapy for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients - John Taylor
Real-World Analysis Confirms Enfortumab Skin Toxicity Predicts Better Survival in Bladder Cancer - Martin Kurian
Trial Explores Nab-paclitaxel/Nivolumab Combination in Cisplatin-Ineligible Bladder Cancer - Chiara Mercinelli
Medley Study Demonstrates Improved PFS of Avelumab-Sacituzumab in Maintenance Setting - Jean Hoffman-Censits
Exploring Immunotherapy Outcomes in Cisplatin-Ineligible Bladder Cancer - Michiel Van Der Heijden
Survey Uncovers Evolving Trends in Advanced Bladder Cancer Care - Ali Raza Khaki
MRI Radiomics Predicts Bladder Cancer Response to Pembrolizumab in PURE-01 Study - Andrea Necchi
CLONEVO Study: Targeting Cyclin D1 Amplifications in Bladder Cancer with Abemaciclib - Bishoy Faltas
Evolving First-Line and Maintenance Strategies in Urothelial Cancer: Insights from ASCO 2025 - Jacqueline Brown
EV-302 Data: High CR Rates and Long-Term Survival with EV-Pembro - Shilpa Gupta
SURE-02 Trial: A Patient-Driven, Bladder-Sparing Approach for MIBC - Andrea Necchi
Multimodal Deep Learning Predicts Bladder Cancer Response to Neoadjuvant Chemotherapy - Bishoy Faltas
SASAN-SPARING Trial: Bladder-Sparing Approach for Muscle-Invasive Bladder Cancer - Elena Sevillano
Real-World EV-301 Data: Enfortumab Vedotin in Trial-Ineligible Patients - Kazutaka Nakamura
Cystectomy vs. Bladder Preservation: Weighing Options for Muscle-Invasive Bladder Cancer - Bogdana Schmidt & Kent Mouw
Practice-Changing Advances in Urothelial Cancer: Highlights Across Disease States - Alice Yu
ctDNA in Bladder Cancer: Prognostic Value and Ongoing Clinical Trials - Jonathan Rosenberg & Petros Grivas
NIAGARA Study: Durvalumab Improves DFS in Muscle-Invasive Bladder Cancer Post-Cystectomy - Joshua Meeks
Complete vs Partial TURBT for Muscle-Invasive Bladder Cancer Treatment - Fredrik Liedberg, Marco Moschini & Benjamin Pradere
Treatment Approaches for Node-Positive Locally Advanced Bladder Cancer - Shilpa Gupta & Felix Guerrero-Ramos
Node-Positive Bladder Cancer: Treatment, Biomarkers, and Surgical Considerations - Neema Navai
A Case-Based Discussion on First-Line EV + Pembrolizumab for Metastatic Urothelial Carcinoma - Neal Shore
NEO-BLAST Trial: Evaluating Bladder Preservation After Neoadjuvant Therapy in Bladder Cancer - Marie-Pier St-Laurent
Circulating Tumor DNA as Prognostic Biomarker in Perioperative Management of Muscle Invasive Bladder Cancer - Nimira Alimohamed
Safety of Combining Radiotherapy with Antibody Drug Conjugates in Advanced Urothelial Carcinoma - Neil Desai
TROPION-PanTumor01 Trial for Advanced Bladder Cancer - Funda Meric-Bernstam
Genomic Characterization of Young-Onset Bladder Cancer - Alina Basnet
Real-World Safety Profiles of First-Line Therapies for Advanced Urothelial Carcinoma - Amanda Nizam
Phase II Trial Results of Disitamab Vedotin and Toripalimab Combination for Muscle-Invasive Bladder Cancer - Xinan Sheng
ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions - Nimira Alimohamed
Avelumab’s Survival Impact in Diabetic vs Non-Diabetic Bladder Cancer Patients - Shilpa Gupta
Adjuvant Nivolumab in High-Risk Muscle Invasive Bladder Cancer Analysis Shows Improved Outcomes for Patients: CheckMate 274 - Matthew Galsky
RETAIN-2 Study Shows Promise for Bladder Cancer Preservation - Pooja Ghatalia
The NIAGARA Trial Highlights the Role of Durvalumab in Bladder Cancer Treatment - Matthew Galsky
Enfortumab Vedotin and Pembrolizumab Demonstrate Durable Responses in Advanced Bladder Cancer - Thomas Powles
Enfortumab Vedotin and Pembrolizumab in Practice: A Case Study in Metastatic Urothelial Carcinoma - Brenda Martone
Adaptive Radiotherapy in Bladder Cancer: Phase II Results from the RAIDER II Trial - Robert Huddart
RETAIN Trial: Sparing Bladder Removal in Muscle-Invasive Bladder Cancer Patients - Daniel Geynisman
Adjuvant Systemic Therapies for Urothelial Carcinoma: Current Evidence and Future Directions - Jean Hoffman-Censits
Serial ctDNA Testing Identifies Bladder Cancer Patients Who May Avoid Adjuvant Therapy - Joaquim Bellmunt
Consolidative Local Therapy in Metastatic Bladder Cancer After Systemic Treatment Response - Fed Ghali
Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer - Jacqueline Brown
Real-World Effectiveness of Enfortumab Vedotin in Advanced Urothelial Carcinoma - Umang Swami
Futibatinib and Pembrolizumab in FGFR-Altered Urothelial Cancer - Vadim Koshkin
Advances in Muscle-Invasive Bladder Cancer: Systemic Therapies and Surgical Innovations - Jen-Jane Liu
Nectin-4 Expression Not Predictive of Response in Enfortumab Vedotin Therapy - Thomas Powles
Lessons Learned from Other Cancers that Can be Applied to Bladder Cancer - Petros Grivas
Emerging Neoadjuvant Combinations for Muscle-Invasive Bladder Cancer - Mamta Parikh
Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract
Study Finds Whole Pelvis Radiotherapy Superior to Bladder-Only in MIBC Treatment - Gautier Marcq
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
Quality of life after Trimodality Therapy - Kimberley Mak
5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103 - Jonathan Rosenberg
NIAGARA Trial Shows Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka
Bridging Evidence to Practice: Bladder Cancer Therapy Guidelines and Global Implementation - Andrea Apolo
SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner
EV-302 Trial Analysis Evaluating Nectin-4 in Urothelial Cancer - Thomas Powles
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
Variant Histology Bladder Cancer Challenges and Future Directions - Syed Hussain
Bladder Cancer Research Explores Fecal Transplants and Nutritional Strategies - Laura Bukavina
Highlights in Non-Prostate GU Oncology from ESMO 2024 - Ignacio Duran
Enfortumab Vedotin and Stereotactic Radiation Tested Before Surgery in Muscle-Invasive Bladder Cancer in STAR-EV Trial - Tian Zhang
Event-Free Survival as Surrogate Endpoint in Muscle Invasive Bladder Cancer Research - Cora Sternberg
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis
SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo
EV-302 Trial Establishes Treatment Standard for Urothelial Carcinoma - Daniel Petrylak
Trimodal Therapy in Urothelial vs Non-Urothelial Bladder Cancer - Mario de Angelis
The Best of ASCO 2024 in Advanced Bladder Cancer - Shilpa Gupta
Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment - Omar Alhalabi
dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications - Elias Chandran
Bladder-Sparing Chemoradiation for Localized Bladder Cancer: Addressing the Unmet Need - Brent Rose
EV-302 Subgroup Analysis: Improved Outcomes for Cisplatin-Ineligible Advanced Urothelial Cancer Patients - Michiel Van der Heijden
SunRISe-2 Trial: TAR-200 and Cetrelimab vs. Chemoradiotherapy for Muscle-Invasive Bladder Cancer - Stephen Williams
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore
Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie
AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser
Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial - Neal Shore
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore
Balancing Bladder Preservation with Effective Treatment in Cancer Care - Petros Grivas
Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla
Stool Microbiome Signature Predicts Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - Filippo Pederzoli & Massimo Alfano
EV-302 Subgroup Analyses: Enfortumab Vedotin + Pembrolizumab Effective Across Patient Subsets in Metastatic Urothelial Cancer - Jonathan Rosenberg
Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg
Preclinical Study Evaluates Enfortumab Vedotin and Sacituzumab Govitecan with Radiation for Bladder Cancer - Kent Mouw
Genomic Tumor Correlates of Response to Trimodal Therapy for Muscle-Invasive Bladder Cancer - Sophia Kamran
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma - Arlene Siefker-Radtke
EV-302: Enfortumab Vedotin + Pembrolizumab Outperforms Chemo in Untreated Advanced Urothelial Cancer - Michiel Simon Van der Heijden
Adjuvant Pembrolizumab in Urothelial Carcinoma: AMBASSADOR Study Findings - Andrea Apolo
Outcomes of Enfortumab Vedotin After Platinum and Avelumab in Bladder Cancer - Amanda Nizam
Combination Maintenance Therapy for Advanced Bladder Cancer Explored in MAIN-CAV Study - Shilpa Gupta
Utilization of Neoadjuvant Chemo Before Cystectomy - Hiten Patel
International Panel Defines Endpoints and Control Arms for Trials in Locally Advanced and Metastatic Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Multi-Disciplinary Panel Defines Clinical Trial Framework for Muscle-Invasive Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Gemcitabine, Cisplatin and Immunotherapy: A Promising Mix for Advanced Bladder Cancer - Guru Sonpavde & Matthew Galsky
Antibody-Drug Conjugate Combination Yields High Response in Advanced Bladder Cancer - Guru Sonpavde & Bradley McGregor
For Bladder Cancer Patients, New Hope From Immunotherapy Innovations from ESMO 2023 - Petros Grivas
The EV-302 Study and the Implications for Metastatic Bladder Cancer Care - Cora Sternberg
EV-103 Study Update: Four-Year Data on Enfortumab Vedotin and Pembrolizumab Combination in Urothelial Cancer - Shilpa Gupta
Outcomes with Immune Checkpoint Inhibitors in Patients with MTAP Alterations in Advanced Urothelial Carcinoma - Rafee Talukder
Enfortumab Vedotin Combination Therapy and Response Rates - Jonathan E. Rosenberg
Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre Zlotta
New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with Second-Line Immune Checkpoint Inhibitors - Beyond the Abstract
The San Raffaele Urologic Oncology Retreat: Examples of ECOG-ACRIN Research Initiatives - Petros Grivas
The TAR-200 Device in Muscle-Invasive Bladder Cancer: Safety, Efficacy, and Future Prospects - Mark D. Tyson, II
Addressing Challenges in Bladder Cancer Surgery: Enhancing Patient Outcomes and Preparing for Recovery - Sarah Psutka
Full Data Analysis of the Biology and Performance of Pre- and Post-Pembrolizumab VI-RADS for Predicting Pathological Response in MIBC: Insights from a Comprehensive Clinical Trials Pipeline - Andrea Necchi
Pros and Cons of Organ-Sparing Cystectomy in Bladder Cancer Patients: Balancing Oncologic and Functional Outcomes - Param Mariappan & Maria Carmen Mir
Long-Term Results of the IMvigor130 Study: Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer – Matthew Galsky
Neoadjuvant Chemo-Immunotherapy Affect on Downstaging in Cisplatin-Eligible and Ineligible MIBC Patients Prior to Definitive Surgery, HCRN GU14-188: Phase Ib/II Study - Jason Brown
Gemcitabine, Cisplatin, and Nivolumab with Selective Bladder Sparing in MIBC: Co-Primary Endpoint Analysis of HCRN GU 16-256 Phase II Trial - Matthew Galsky
Exploring Genetic Biomarkers of Response to Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of UNITE Dataset - Tanya Jindal & Vadim Koshkin
Assessing the Impact of Enfortumab Vedotin and Pembrolizumab on QoL and Symptom Management in Urothelial Carcinoma: EV-103 Cohort K Study Results - Matthew Milowsky
The Phase 1B NABUCCO Trial: The Use of Either High or Low-Dose Preoperative Ipilimumab plus Nivolumab in Patients with Stage III Urothelial Cancer – Michiel Van Der Heijden
Extended Follow-Up Results of the CheckMate 274 Trial: Adjuvant Nivolumab for Resected Muscle-Invasive Urothelial Carcinoma - Matthew Galsky
Long-Term Follow-up from the JAVELIN Bladder 100 Trial - Srikala Sridhar
The Association Between FGFR3 Alterations and Response to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma - Gopa Iyer
The Use of Biomarkers in the Adjuvant Setting to Understand the Effect of Nivolumab in the Checkmate 274 Study - Andrea Necchi
Results from the Phase 1b/2 FIDES-02 Study: Derazantinib for Metastatic Bladder Cancer with Activating FGFR1/2/3 Genetic Aberrations - Andrea Necchi
The Role of Avelumab Switch Maintenance Immunotherapy in the Front-Line Space of Patients with Advanced Urothelial Cancer - Srikala Sridhar
TROPHY-U-01 Cohort 3 Primary Analysis Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Therapy - Petros Grivas
The Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma - Andrea Apolo
Discoveries Transforming Treatment Options for Advanced Urothelial Carcinoma - Shilpa Gupta
Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Guru Sonpavde
Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen
Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen
CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
ATLANTIS Trial Explores Precision Medicine in Urothelial Carcinoma - Robert Jones
Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis
Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
Navigating the Complex Landscape of Adjuvant Trials in Urothelial Carcinoma - Robert Dreicer
The Role of ctDNA in Metastatic Urothelial Cancer - Alexander Wyatt
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa
Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye
Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose
The Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in the Treatment of Cisplatin-Ineligible Patients in Advanced Urothelial Carcinoma (LEAP-011) - Yohann Loriot
Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde
Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas
Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary Klaassen
Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt
Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander
Beyond Clinical Trials: Real-World Success with Trimodality Therapy in Bladder Cancer - Sean Sachdev & Praneet Polineni
Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor
Advances in the Treatment of Metastatic Urothelial Cancer - Matthew Galsky
Breaking Down the TROPHY-U-01 Trial: How Sacituzumab Govitecan Earned FDA Approval for Advanced Bladder Cancer - Neeraj Agarwal & Petros Grivas
Intersection of Biology and Clinical Characteristics Towards Personalized Sequential Treatments for MIBC - Andrea Necchi and Ewan Gibb
The Role of Imaging in Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: A Case Study of PURE-01 - Andrea Necchi & Laura Marandino
TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa
Chemoradiation in Urothelial Carcinoma: The Herculean Effort Behind the SWOG 1806 Trial - Petros Grivas
Variant Histologies of Bladder Cancer - Petros Grivas
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas
Operationalizing the Use of Avelumab in Clinical Practice, The Phase III JAVELIN Bladder 100 Trial - Brenda Martone
Characterization of The Genomic Landscape of Post-Neoadjuvant Chemotherapy in MIBC Patients- Andrew Lenis
Metastatic and Muscle-Invasive Bladder Cancer European Association of Urology (EAU) Guidelines - J. Alfred Witjes
Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo
Molecular Changes Associated with Treatment Response in Muscle-Invasive Bladder Cancer Patients Treated with Cisplatin-Based Chemotherapy - Lars Dyrskjøt
Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden
Evaluating Treatments in Advanced Urothelial Carcinoma - Guru Sonpavde
Association Between Clinical Outcomes and Exploratory Biomarkers in the JAVELIN Bladder 100 Trial, Advanced Urothelial Carcinoma - Srikala Sridhar
ESMO 2020: The TROPHY-U-01 Study- Sacituzumab Govitecan for Advanced Urothelial Carcinoma - Petros Grivas
ESMO 2020: Combination Therapies in Locally Advanced or Metastatic Urothelial Carcinoma Bladder Cancer - Josh Meeks
Current Treatment Approaches in Advanced Urothelial Carcinoma - Shilpa Gupta
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
Treatment Approach: Case Study in Aggressiveness Metastatic Urothelial Carcinoma - Makarand Khochikar
Prolonging Overall Survival in Patients with Muscle-Invasive Bladder Cancer - Petros Grivas
Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Assessing the Potential Cost-Effectiveness of the Addition of Atezolizumab to First-Line Platinum Chemotherapy in Advanced Urothelial Carcinoma - Ali Khaki
Progress in Bladder Cancer Research - Bishoy Faltas
IMvigor010 Primary Analysis from a Phase III Randomized Study of Adjuvant Atezolizumab versus Observation in High-Risk Muscle-Invasive Urothelial Carcinoma - Thomas Powles & Matthew Galsky
JAVELIN Bladder 100: Avelumab for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma - Thomas Powles
Controversial and Complex Cases in Urothelial Cancer - Srikala Sridhar
The Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in MIBC - Andrea Necchi
The Landscape of Advanced Bladder Cancer: A Review of the Last 30-Years - Cora Sternberg
Enfortumab Vedotin for Advanced Urothelial Carcinoma - Jonathan Rosenberg
Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky
Recent Advances in the Treatment of Metastatic Urothelial Cancer - Petros Grivas
Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo
Advanced Bladder Cancer Clinic: Are you Ready? - Neal Shore
The Performance Status and Response to Immune Checkpoint Inhibition in Patients with Advanced Urothelial Carcinoma - Ali Khaki
Immunotherapy and Chemotherapy Use in Patients with Metastatic Bladder Cancer - Ronac Mamtani and Ravi Parikh
Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas
Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky
Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas
Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas
Optimizing Treatment Outcomes in Muscle Invasive Bladder Cancer (MIBC) - Wassim Kassouf
Antibody Drug Conjugates for the Treatment of Metastatic Urothelial Carcinoma - Petros Grivas
Treating Advanced Bladder Cancer - Petros Grivas
Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg
Novel New Approaches in the Neoadjuvant Disease Setting for Bladder Cancer - Petros Grivas
Bladder Sparing Strategies for Urothelial Cancer - Jason Efstathiou
Urinary Diversion after Radical Cystectomy - Morgan Roupret
Assessing and Managing Toxicities with Immune Checkpoint Inhibitors - Brenda Martone
Neoadjuvant Treatment in Muscle Invasive Bladder Cancer- Andrea Necchi
Erdafitinib in Bladder Cancer - Arjun Balar
Implications of Clinical Response Following Neoadjuvant Chemotherapy - Seth Lerner
Joshua J. Meeks on SWOG 1806 Study
Antibody-drug Conjugate (ADC) Sacituzumab Govitecan in Metastatic UroThelial Carcinoma - Scott Tagawa
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer - Matthew Galsky
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo
A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas
Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg
Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar